Greater Glasgow and Clyde Medicines

Formulary Search Results for: BUPRENORPHINE 4.7.2

4.7.2 Opioid analgesics - View Category

Total Formulary
BUPRENORPHINE (7-day transdermal patch)

Restrictions:

Treatment of chronic non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia is restricted to use only in elderly patients (over 65 years) where standard analgesic options are ineffective or not tolerated.

Prescribing Notes:

  • There are several brands of buprenorphine transdermal patches. They are not all interchangeable and can vary in relation to the frequency of application. To avoid confusion and the potential for dosing errors, buprenorphine transdermal patches should be prescribed by brand name.
  • In NHSGGC Sevodyne® is the preferred brand of 7-day patch

BNF Link

4.7.2 Opioid analgesics - View Category

Total Formulary
PETHIDINE

4.7.2 Opioid analgesics - View Category

Preferred List
DIAMORPHINE (injection)

4.7.2 Opioid analgesics - View Category

Preferred List
CODEINE PHOSPHATE

4.10.3 Opioid dependence - View Category

Total Formulary
BUPRENORPHINE (sublingual tablets)

Restrictions:

Restricted to specialist services (GGC Alcohol and Drug Services).

BNF Link

4.10.3 Opioid dependence - View Category

Preferred List
Specialist and GP
BUPRENORPHINE (prolonged-release injection)

Restrictions:

Restricted to use on advice of specialist from the GGC Alcohol and Drug Services.

BNF Link

4.10.3 Opioid dependence - View Category

Preferred List
Specialist and GP
BUPRENORPHINE (ESPRANOR) (ORAL LYOPHILISATE)

Restrictions:

Restricted to use on advice of specialist from the GGC Alcohol and Drug Services.

BNF Link

4.7.2 Opioid analgesics - View Category

Preferred List
MORPHINE

Prescribing Notes:

  • Modified-release preparations should be prescribed by brand name.  The preferred choice of solid morphine sulphate MR across primary and secondary care in NHSGGC is Zomorph®
  • Immediate release Actimorph® is available on advice of the palliative care team when administration of low doses with oral morphine liquid is deemed unsuitable

BNF Link

4.7.2 Opioid analgesics - View Category

Preferred List
OXYCODONE HYDROCHLORIDE (oral formulations)

Restrictions:

Use is restricted to patients in whom morphine is ineffective or not tolerated. The combination product of oxycodone and naloxone (Targinact®) is not recommended for use in NHS Scotland by the SMC and is non-Formulary.

Prescribing Notes:

  • Tablets and capsules should be prescribed by brand name and the current brands of choice for modified-release and immediate release preparations respectively are Oxypro® and Shortec®.
  • Oral liquid is no longer available as the Shortec® brand. Please prescribe generically to allow timely supply of other available brands.

BNF Link